Lenalidomide for the treatment of mantle cell lymphoma-Reference-Cited by-同舟云学术

Lenalidomide for the treatment of mantle cell lymphoma

Published:2019-01-04 Issue:5 Volume:20 Page:487-494
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Morabito Fortunato¹²,Skafi Mamdouh¹,Recchia Anna Grazia²,Kashkeesh Aya³,Hindiyeh Musa⁴,Sabatleen Ali⁵,Morabito Lucio⁶,Alijanazreh Hamdi¹,Hamamreh Yousef⁷,Gentile Massimo²⁸

Affiliation:

1. Hematogy Department and Bone Marrow Transplant Unit, Cancer Care Center, Augusta Victoria Hospital, East Jerusalem, Israel

2. Biotechnology Research Unit, AO, Cosenza, Italy

3. Quality managment Office, Augusta Victoria Hospital, East Jerusalem, Israel

4. Laboratory Department, Augusta Victoria Hospital, East Jerusalem, Israel

5. Infectious Disease Department, Augusta Victoria Hospital, East Jerusalem, Israel

6. Hematology Unit, Humanitas Cancer Center, Rozzano, Italy

7. Clinical Oncology Department, Cancer Care Center, Augusta Victoria Hospital, East Jerusalem, Israel

8. Hematology Unit, AO, Cosenza, Italy

Funder

not been funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2018.1561865

Reference71 articles.

1. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

2. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

3. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

4. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis

5. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study;Hematology Reports;2024-01-18

2. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy;World Journal of Clinical Oncology;2023-12-24

3. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects;Critical Reviews in Oncology/Hematology;2023-10

4. Measurement of the Thermal Conductivities of Methyl 2-Methyl-3-nitrobenzoate + Acetonitrile, N-Bromosuccinimide + Acetonitrile, and Methyl 2-Methyl-3-nitrobenzoate + N-Bromosuccinimide + Acetonitrile in the Temperature Range from 300 to 340 K;Journal of Chemical & Engineering Data;2023-09-13

5. Lenalidomide potentially reduced the level of cell- associated HIV RNA and improved persistent inflammation in patients with HIV-associated cryptococcal meningitis a pilot study;Frontiers in Cellular and Infection Microbiology;2022-07-28